An Overview on Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases

Document Type : Review Paper

Authors

1 Food and Drug Laboratory Research Center, Iran Food and Drug Organization (FDO), Ministry of Health and Medical Education (MOH), Tehran, Iran. Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran.

3 Food and Drug Cosmetic Research Center, Iran Food and Drug Organization (FDO), Ministry of Health and Medical Education (MOH), Tehran, Iran.

4 Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran,Iran.

5 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

6 Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

7 Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran. Iran.

8 Evidence-based Evaluation of Cost-Effectiveness and Clinical Outcomes, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.

9 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

10 Department of Medicine and epidemiology, School of veterinary Medicine, University of California, Davis, USA.

Abstract

Aims: Probiotics are viable and useful microorganisms, which are beneficial factors for human and animal health by altering their microbial flora. Most of the probiotics belong to a large group of bacteria in the human gastrointestinal tract. There are several clinical shreds of evidence that show anti-carcinogenic effects of probiotics through altering digestive enzymes, inhibition of carcinogenic agents and modulating the immune responses in experimental animals. Many studies performed to evaluate the potential effectiveness of probiotics in treating or preventing neurological diseases such as MS and novel treatment modality for T1D.
The purpose of this study is to have an overview on probiotic microorganisms and to review the previous researches on the effects of probiotics on health through currently available literatures.
Methods: The study was performed using following keywords; Probiotics, Cancer, Immune system, Multiple Sclerosis and Diabetes mellitus. PubMed/Medline, Clinicaltrials.gov, Ovid, Google Scholar, and Reaxcys databases used to find the full text of related articles.
Results and Conclusion: according to the current available data on probiotics and related health-promoting benefits, it seems that, consumption of probiotics can lead to the prevention and reduction the risk of cancer, diabetes, and multiple sclerosis. Although for the better and more decisive conclusion, there is a need to larger sample size clinical studies with more focus on the safety of these biological agents and their possible beneficial effects on different population.

Keywords

Main Subjects


1. Sarowska J, Choroszy-Król I, Regulska-Ilow
B, Frej-Madrzak M and Jama-Kmiecik A.
The therapeutic effect of probiotic bacteria on
gastrointestinal diseases. Adv. Clin. Exp. Med.
(2013) 22: 759-66.
2. Ozen M, Dinleyici E. The history of probiotics: the
untold story. Benef Microbes. (2015) 6: 159-65.
3. McFarland LV. From yaks to yogurt: the history,
development, and current use of probiotics. Clin
Infect Dis. (2015) 60(suppl_2):S85-S90.
4. Stambler I. A History of Life-extensionism in the
Twentieth Century: CreateSpace Independent
Publishing Platform (2014).
5. Nair BM and Prajapati JB. The history of fermented
foods. Handbook of fermented functional foods,
CRC Press (2003).
6. Wallace TC, Guarner F, Madsen K, Cabana MD,
Gibson G and Hentges E and Sanders ME. Human
gut microbiota and its relationship to health and
disease. Nutr. Rev. (2011) 69:392-403.
7. Swan M. Health 2050: the realization of
personalized medicine through crowdsourcing, the
quantified self, and the participatory biocitizen. J.
Pers. Med. (2012) 2: 93-118.
8. Gibson GR, Scott KP, Rastall RA, Tuohy KM,
Hotchkiss A, Dubert-Ferrandon A, Gareau M,
Murphy EF, Saulnier D, Loh G, Macfarlane S,
Delzenne N, Ringel Y, Kozianowski G, Dickman
R, Lenoir-Wijnkoop I, Walker C and Buddington
R. Dietary prebiotics: current status and new
definition. J. Food. Sci. Technol. (2010) 7: 1-19.
9. Ranadheera R, Baines S and Adams M. Importance
of food in probiotic efficacy. Food. Res. Int. (2010)
43: 1-7.
10. Pandey KR, Naik SR and Vakil BV. Probiotics,
prebiotics and synbiotics-a review. J. Food. Sci.
Technol. (2015) 52: 7577-87.
11. Ambalam P, Raman M, Purama RK and Doble
M. Probiotics, prebiotics and colorectal cancer
prevention. Best. Pract. Res. Clin. Gastroenterol.
(2016) 30: 119-31.
12. Bengmark S. Gut microbiota, immune development
and function. Pharmacol. Res. (2013)69: 87-113.
13. Sanders ME, Akkermans LM, Haller D,
Hammerman C, Heimbach J, Hörmannsperger
G, Huys G, Levy DD, Lutgendorff F, Mack D,
Phothirath P, Solano-Aguilar G and Vaughan E.
Safety assessment of probiotics for human use.
Gut. Microbes. (2010) 1: 164-85.
14. Cook MT, Tzortzis G, Charalampopoulos D
and Khutoryanskiy VV. Microencapsulation of
probiotics for gastrointestinal delivery. J. Control.
Release. (2012) 162: 56-67.
15. Dinleyici EC, Eren M, Ozen M, Yargic ZA
and Vandenplas Y. Effectiveness and safety of
Saccharomyces boulardii for acute infectious
diarrhea. Expert. Opin. Biol. Ther. (2012) 12: 395-
410.
16. Jankovic I, Sybesma W, Phothirath P, Ananta E
and Mercenier A. Application of probiotics in food
products—challenges and new approaches. Curr.
Opin. Biotechnol. (2010) 21: 175-81.
17. Williams NT. Probiotics. Am. J. Health. Syst.
Pharm. (2010) 67: 22-8.
18. Hickson M. Probiotics in the prevention of
antibiotic-associated diarrhoea and Clostridium
difficile infection. Therap. Adv. Gastroenterol.
(2011) 4: 185-97.
19. Kamada N, Seo S-U, Chen GY and Núñez G. Role
of the gut microbiota in immunity and inflammatory
disease. Nat. Rev. Immunol. (2013)13: 321-35.
20. Uccello M, Malaguarnera G, Basile F, D’agata V,
Malaguarnera M, Bertino G, Vacante M, Drago
F and Biondi A. Potential role of probiotics on
colorectal cancer prevention. BMC. Surg. (2012)
12: S35.
46
Taherian M et al. / IJPR (2019), 18 (Special Issue): 31-50
21. Merrifield DL, Dimitroglou A, Foey A, Davies SJ,
Baker RT and Bøgwald J. The current status and
future focus of probiotic and prebiotic applications
for salmonids. Aquaculture (2010) 302: 1-18.
22. Cryan JF and Dinan TG. Mind-altering
microorganisms: the impact of the gut microbiota
on brain and behaviour. Nat. Rev. Neurosci. (2012)
13: 701-12.
23. Oelschlaeger TA. Mechanisms of probiotic
actions–a review. Int. J. Med. Microbiol. (2010)
300: 57-62.
24. Kumar M, Kumar A, Nagpal R, Mohania D, Behare
P, Verma V, Kumar P, Poddar D, Aggarwal PK,
Henry CJ, Jain S and Yadav H. Cancer-preventing
attributes of probiotics: an update. Int. J. Food. Sci.
Nutr. (2010) 61: 473-96.
25. Davis CD and Milner JA. Gastrointestinal
microflora, food components and colon cancer
prevention. J. Nutr. Biochem. (2009) 20: 743-52.
26. Turpin W, Humblot C, Thomas M and Guyot J-P.
Lactobacilli as multifaceted probiotics with poorly
disclosed molecular mechanisms. Int. J. Food.
Microbiol. (2010) 143: 87-102.
27. Pantel K and Alix-Panabières C. Circulating
tumour cells in cancer patients: challenges and
perspectives. Trends. Mol. Med. (2010) 16: 398-
406.
28. Lobo V, Patil A, Phatak A and Chandra N. Free
radicals, antioxidants and functional foods: Impact
on human health. Pharmacogn. Rev. (2010) 4: 118.
29. Yu H. Bacteria-mediated disease therapy. Appl.
Microbiol. Biotechnol. (2011) 92:1107-13.
30. Urbanska AM, Zhang X and Prakash S.
Bioengineered colorectal cancer drugs: orally
delivered anti-inflammatory agents. Cell. Biochem.
Biophys. (2015) 72:757-69.
31. Maulik N and Karagiannis T. Molecular
mechanisms and physiology of disease: Springer
(2014).
32. Masood MI, Qadir MI, Shirazi JH and Khan IU.
Beneficial effects of lactic acid bacteria on human
beings. Crit. Rev. Microbiol. (2011) 37: 91-8.
33. Havenaar R. Intestinal health functions of colonic
microbial metabolites: a review. Beneficial
Microbes. (2011) 2:103-14.
34. Abrahamse S, Pool-Zobel B and Rechkemmer G.
Potential of short chain fatty acids to modulate
the induction of DNA damage and changes
in the intracellular calcium concentration by
oxidative stress in isolated rat distal colon cells.
Carcinogenesis. (1999) 20: 629-34.
35. Di Cerbo A, Palmieri B, Aponte M, MoralesMedina JC and Iannitti T. Mechanisms and
therapeutic effectiveness of lactobacilli. J. Clin.
Pathol. (2016) 69: 187-203.
36. Bhatt AP, Redinbo MR and Bultman SJ. The role
of the microbiome in cancer development and
therapy. CA. Cancer. J. Clin. (2017) 67: 326-44.
37. Azcárate-Peril MA, Sikes M and Bruno-Bárcena
JM. The intestinal microbiota, gastrointestinal
environment and colorectal cancer: a putative role
for probiotics in prevention of colorectal cancer?
Am. J. Physiol. Gastrointest. Liver. Physiol. (2011)
301: G401-G24.
38. Ghoneum M and Gollapudi S. Phagocytosis of
Candida albicans by metastatic and non metastatic
human breast cancer cell lines in-vitro. Cancer
Detect. Prev. (2004) 28: 17-26.
39. Henderson AJ, Ollila CA, Kumar A, Borresen
EC, Raina K and Agarwal R. Chemopreventive
properties of dietary rice bran: current status and
future prospects. Adv. Nutr. (2012) 3: 643-53.
40. Ghoneum M, Wang L, AGRAWAL S and Gollapudi
S. Yeast therapy for the treatment of breast cancer:
a nude mice model study. In-vivo. (2007) 21: 251-
8.
41. Saber A, Alipour B, Faghfoori Z and Yari
Khosroushahi A. Cellular and molecular effects
of yeast probiotics on cancer. Crit. Rev. Microbiol.
(2017) 43: 96-115.
42. Ghoneum M, Matsuura M, Braga M and
Gollapudi SS. cerevisiae induces apoptosis in
human metastatic breast cancer cells by altering
intracellular Ca2+ and the ratio of Bax and Bcl-2.
Int. J. Oncol. (2008) 33: 533-9.
43. Bonyadi F, Nejati V, Tukmechi A, Hasanzadeh
S and Mokarizadeh A. An investigation of the
complex effects of a Saccharomyces cerevisiae
cytoplasmic extract on apoptosis in K562 cells.
Iran. Red. Crescent. Med. J. (2017) 19: e28773.
44. Zhong L, Zhang X and Covasa M. Emerging
roles of lactic acid bacteria in protection against
colorectal cancer. World. J. Gastroenterol. (2014)
20: 7878.
45. Raman M, Ambalam P, Kondepudi KK, Pithva S,
Kothari C and Patel AT. Potential of probiotics,
prebiotics and synbiotics for management of
colorectal cancer. Gut Microbes. (2013) 4: 181-92.
46. Selvin E, Marinopoulos S, Berkenblit G, Rami
T, Brancati FL, Powe NR and Golden SH.
Meta-analysis: glycosylated hemoglobin and
cardiovascular disease in diabetes mellitus. Ann.
Intern. Med (2004) 141: 421-31.
47. Hu FB. Globalization of Diabetes: The role of
diet, lifestyle, and genes. Diabetes Care (2011) 34:
1249-57.
48. Guariguata L, Whiting DR, Hambleton I, Beagley
J, Linnenkamp U and Shaw JE. Global estimates of 
47
Probiotics for Prevention and Treatment of Human Diseases
diabetes prevalence for (2013) and projections for
2035. Diabetes Res. Clin. Pract. (2014) 103: 137-
49.
49. Asif M. The prevention and control the type-2
diabetes by changing lifestyle and dietary pattern.
J. Educ. Health. Promot. (2014) 31: 1.
50. Gonder-Frederick L. Lifestyle Modifications in the
Management of Type 1 Diabetes: Still Relevant
After All These Years? Diabetes Technol. Ther.
(2014) 16: 695-8.
51. Gerritsen J, Smidt H, Rijkers GT and de Vos WM.
Intestinal microbiota in human health and disease:
the impact of probiotics. Genes. Nutr. (2011) 6:
209-40.
52. Krzewska A and Ben-Skowronek I. Effect of
Associated Autoimmune Diseases on Type 1
Diabetes Mellitus Incidence and Metabolic Control
in Children and Adolescents. Biomed. Res. Int.
(2016) 2016: 6219730.
53. Atkinson MA. The Pathogenesis and Natural
History of Type 1 Diabetes. Cold. Spring. Harb.
Perspect. Med. (2012) 2: pii: a007641.
54. Raha O, Chowdhury S, Dasgupta S, Raychaudhuri
P, Sarkar BN, Raju PV and Rao VR. Approaches
in type 1 diabetes research: A status report. Int. J.
Diabetes. Dev. Ctries. (2009) 29: 85-101.
55. Precechtelova J, Borsanyiova M, Sarmirova S and
Bopegamage S. Type I diabetes mellitus: genetic
factors and presumptive enteroviral etiology or
protection. J. Pathog. (2014) (2014): 738512.
56. Cabrera SM, Rigby MR and Mirmira RG. targeting
regulatory t cells in the treatment of type 1 diabetes
mellitus. Curr. Mol. Med. (2012) 12: 1261-72.
57. Amer LD, Mahoney MJ and Bryant SJ. Tissue
Engineering Approaches to Cell-Based Type 1
Diabetes Therapy. Tissue. Eng. Part. B. Rev. (2014)
20: 455-67.
58. Shapiro AM, Pokrywczynska M and Ricordi C.
Clinical pancreatic islet transplantation. Nat. Rev.
Endocrinol. (2017) 13: 268-77.
59. Yoon JW and Jun HS. Autoimmune destruction of
pancreatic beta cells. Am. J. Ther. (2005) 12: 580-
91.
60. Lebastchi J and Herold KC. Immunologic and
Metabolic Biomarkers of β-Cell Destruction in the
Diagnosis of Type 1 Diabetes. Cold. Spring. Harb.
Perspect. Med. (2012) 2: a007708.
61. Pirot P, Cardozo AK and Eizirik DL. Mediators and
mechanisms of pancreatic beta-cell death in type 1
diabetes. Arq. Bras. Endocrinol. Metabol. (2008)
52:156-65.
62. Ramachandran A, Snehalatha C, Shetty AS and
Nanditha A. Trends in prevalence of diabetes in
Asian countries. World. J. Diabetes. (2012) 3: 110-7.
63. Lee R, Wong TY and Sabanayagam C.
Epidemiology of diabetic retinopathy, diabetic
macular edema and related vision loss. Eye Vision
(2015) 2: 17.
64. Stuckler D. Population Causes and Consequences
of Leading Chronic Diseases: A Comparative
Analysis of Prevailing Explanations. Milbank. Q.
(2008) 86: 273-326.
65. Atkinson MA, Eisenbarth GS and Michels AW.
Type 1 diabetes. Lancet (2014) 383: 69-82.
66. Bekkering P, Jafri I, van Overveld FJ and Rijkers
GT. The intricate association between gut
microbiota and development of type 1, type 2 and
type 3 diabetes. Expert. Rev. Clin. Immunol. (2013)
9: 1031-41.
67. Jia W, Li H, Zhao L and Nicholson JK. Gut
microbiota: a potential new territory for drug
targeting. Nat. Rev. Drug. Discov. (2008) 7: 123-9.
68. Giongo A, Gano KA, Crabb DB, Mukherjee N,
Novelo LL, Casella G, Drew JC, Ilonen J, Knip
M, Hyöty H, Veijola R, Simell T, Simell O, Neu
J, Wasserfall CH, Schatz D, Atkinson MA and
Triplett EW. Toward defining the autoimmune
microbiome for type 1 diabetes. ISME J. (2011) 5:
82-91.
69. Ljungberg M, Korpela R, Ilonen J, Ludvigsson
J and Vaarala O. Probiotics for the prevention of
beta cell autoimmunity in children at genetic risk
of type 1 diabetes--the PRODIA study. Ann. N. Y.
Acad. Sci. (2006) 1079: 360-4.
70. Martins TC and Aguas AP. Changes in B and
T lymphocytes associated with mycobacteriainduced protection of NOD mice from diabetes. J.
Autoimmun. (1996) 9: 501-7.
71. Satoh J, Shintani S, Oya K, Tanaka S, Nobunaga T,
Toyota T and Goto Y. Treatment with streptococcal
preparation (OK-432) suppresses anti-islet
autoimmunity and prevents diabetes in BB rats.
Diabetes (1988) 37: 1188-94.
72. King C and Sarvetnick N. The incidence of type-1
diabetes in NOD mice is modulated by restricted
flora not germ-free conditions. PLoS. One. (2011)
6: e17049.
73. Alyanakian MA, Grela F, Aumeunier A, Chiavaroli
C, Gouarin C, Bardel E, Normier G, Chatenoud L,
Thieblemont N and Bach JF. Transforming growth
factor-beta and natural killer T-cells are involved in
the protective effect of a bacterial extract on type 1
diabetes. Diabetes (2006) 55: 179-85.
74. Brugman S, Klatter FA, Visser JT, WildeboerVeloo AC, Harmsen HJ, Rozing J and Bos NA.
Antibiotic treatment partially protects against type
1 diabetes in the Bio-Breeding diabetes-prone rat.
Is the gut flora involved in the development of type 
48
Taherian M et al. / IJPR (2019), 18 (Special Issue): 31-50
1 diabetes? Diabetologia (2006) 49: 2105-8.
75. Roesch LF, Lorca GL, Casella G, Giongo A,
Naranjo A, Pionzio AM, Li N, Mai V, Wasserfall
CH, Schatz D, Atkinson MA, Neu J and Triplett EW.
Culture-independent identification of gut bacteria
correlated with the onset of diabetes in a rat model.
ISME J. (2009) 3: 536-48.
76. Al-Salami H, Butt G, Fawcett JP, Tucker IG,
Golocorbin-Kon S and Mikov M. Probiotic
treatment reduces blood glucose levels and
increases systemic absorption of gliclazide in
diabetic rats. Eur. J. Drug. Metab. Pharmacokinet.
(2008) 33: 101-6.
77. Tlaskalová-Hogenová H, Stěpánková R, Kozáková
H, Hudcovic T, Vannucci L, Tučková L, Rossmann
P, Hrnčíř T, Kverka M, Zákostelská Z, Klimešová
K, Přibylová J, Bártová J, Sanchez D, Fundová
P, Borovská D, Srůtková D, Zídek Z, Schwarzer
M, Drastich P and Funda DP. The role of gut
microbiota (commensal bacteria) and the mucosal
barrier in the pathogenesis of inflammatory and
autoimmune diseases and cancer: contribution of
germ-free and gnotobiotic animal models of human
diseases. Cell. Mol. Immunol. (2011) 8:110-20.
78. Wu HJ and Wu E. The role of gut microbiota in
immune homeostasis and autoimmunity. Gut.
Microbes. (2012) 3: 4-14.
79. Bhattacharyya A, Chattopadhyay R, Mitra S and
Crowe SE. Oxidative Stress: An Essential Factor
in the Pathogenesis of Gastrointestinal Mucosal
Diseases. Physiol. Rev. (2014) 94: 329-54.
80. Park CO and Kupper TS. The emerging role of
resident memory T cells in protective immunity
and inflammatory disease. Nat. Med. (2015) 21:
688-97.
81. Linden SK, Sutton P, Karlsson NG, Korolik V and
McGuckin MA. Mucins in the mucosal barrier to
infection. Mucosal. Immunol. (2008) 1: 183-97.
82. Rahman AH, Taylor DK and Turka LA. The
contribution of direct TLR signaling to T cell
responses. Immunol. Res. (2009) 45: 25-36.
83. Burrows MP, Volchkov P, Kobayashi KS and
Chervonsky AV. Microbiota regulates type 1
diabetes through Toll-like receptors. Proc. Natl.
Acad. Sci. USA (2015) 112: 9973-7.
84. Mogensen TH. Pathogen Recognition and
Inflammatory Signaling in Innate Immune
Defenses. Clin. Microbiol. Rev. (2009) 22: 240-73.
85. McCall AL and Farhy LS. Treating type 1
diabetes: from strategies for insulin delivery to dual
hormonal control. Minerva. Endocrinol. (2013) 38:
145-63.
86. Tian C, Bagley J, Cretin N, Seth N, Wucherpfennig
KW and Iacomini J. Prevention of type 1 diabetes
by gene therapy. J. Clin. Invest. (2004) 114: 969-
78.
87. Mejía-León ME and Calderón de la Barca AM.
Diet, Microbiota and Immune System in Type 1
Diabetes Development and Evolution. Nutrients
(2015) 7: 9171-84.
88. Fouhy F, Ross RP, Fitzgerald GF, Stanton C and
Cotter PD. Composition of the early intestinal
microbiota: Knowledge, knowledge gaps and the
use of high-throughput sequencing to address these
gaps. Gut. Microbes. (2012) 3: 203-20.
89. Peng L, Li ZR, Green RS, Holzman IR and Lin
J. Butyrate Enhances the Intestinal Barrier by
Facilitating Tight Junction Assembly via Activation
of AMP-Activated Protein Kinase in Caco-2 Cell
Monolayers. J. Nutr. (2009) 139: 1619-25.
90. Canani RB, Costanzo MD, Leone L, Pedata M, Meli
R and Calignano A. Potential beneficial effects of
butyrate in intestinal and extraintestinal diseases.
World. J. Gastroenterol. (2011) 17: 1519-28.
91. Diagnosis and Classification of Diabetes Mellitus.
Diabetes. Care. (2009) 32(Suppl 1): S62-7.
92. Cantley J and Ashcroft FM. Q&A: insulin
secretion and type 2 diabetes: why do β-cells fail?
BMC. Biol. (2015)13: 33.
93. Esteghamati A, Gouya MM, Abbasi M, Delavari
A, Alikhani S, Alaedini F, Safaie A, Forouzanfar
M an Gregg EW. Prevalence of diabetes and
impaired fasting glucose in the adult population
of Iran: National Survey of Risk Factors for NonCommunicable Diseases of Iran. Diabetes Care
(2008) 31: 96-8.
94. Olokoba AB, Obateru OA and Olokoba LB. Type
2 Diabetes Mellitus: A Review of Current Trends.
Oman. Med. J. (2012) 27: 269-73.
95. Boulangé CL, Neves AL, Chilloux J, Nicholson
JKand Dumas ME. Impact of the gut microbiota
on inflammation, obesity, and metabolic disease.
Genome. Med. (2016) 8: 48-51.
96. Martín-Timón I, Sevillano-Collantes C, SeguraGalindo A and del Cañizo-Gómez FJ. Type 2
diabetes and cardiovascular disease: Have all risk
factors the same strength? World. J. Diabetes.
(2014) 5: 444-70.
97. Kaur J. A Comprehensive Review on Metabolic
Syndrome. Cardiol. Res. Pract. (2014) 2014:
943162.
98. Sharma D, Garg S, Mehndiratta M, S VM and
Puri D. Relationship of Serum Apolipoprotein
A-V Levels, Oxidative Stress and Inflammatory
Biomarkers with Hypertriglyceridemia in Type
2 Diabetes Mellitus. Int. J. Endocrinol. Metab.
(2017) 15: e44805.
99. Teixeira-Lemos E, Nunes S, Teixeira F and Reis 
49
Probiotics for Prevention and Treatment of Human Diseases
F. Regular physical exercise training assists in
preventing type 2 diabetes development: focus on
its antioxidant and anti-inflammatory properties.
Cardiovasc. Diabetol. (2011) 10: 12.
100. Tabatabai A and Li S. Dietary fiber and type 2
diabetes. Clin. Excell. Nurse. Pract. (2000) 4:
272-6.
101. Vinik AI and Jenkins DJ. Dietary fiber in
management of diabetes. Diabetes Care (1988) 11:
160-73.
102. Johnson AR, Milner JJ and Makowski L. The
inflammation highway: metabolism accelerates
inflammatory traffic in obesity. Immunol. Rev.
(2012) 249: 218-38.
103. Mazloom Z, Yousefinejad A and Dabbaghmanesh
MH. Effect of Probiotics on Lipid Profile,
Glycemic Control, Insulin Action, Oxidative
Stress, and Inflammatory Markers in Patients with
Type 2 Diabetes: A Clinical Trial. Iran. J. Med. Sci.
(2013) 38: 38-43.
104. Ostadrahimi A, Taghizadeh A, Mobasseri M,
Farrin N, Payahoo L, Beyramalipoor Gheshlaghi Z
and Vahedjabbari M. Effect of Probiotic Fermented
Milk (Kefir) on Glycemic Control and Lipid
Profile In Type 2 Diabetic Patients: A Randomized
Double-Blind Placebo-Controlled Clinical Trial.
Iran. J. Public. Health. (2015) 44: 228-37.
105. Brown AC, Shovic A, Ibrahim S, Holck P and
Huang A. a non-dairy probiotic’s (poi) influence
on changing the gastrointestinal tract’s microflora
environment. Altern. Ther. Health. Med. (2005) 11:
58-64.
106. Ruan Y, Sun J, He J, Chen F, Chen Rand Chen
H. Effect of Probiotics on Glycemic Control:
A Systematic Review and Meta-Analysis of
Randomized, Controlled Trials. PLoS. One. (2015)
10: e0132121.
107. Gomes AC, Bueno AA, de Souza RGMand Mota
JF. Gut microbiota, probiotics and diabetes. Nutr.
J. (2014) 13: 60.
108. Mohamadshahi M. Effects of probiotic yogurt
consumption on inflammatory biomarkers in
patients with type 2 diabetes. Bioimpacts (2014) 4:
83-8.
109. Isolauri E, Kirjavainen P and Salminen S.
Probiotics: a role in the treatment of intestinal
infection and inflammation? Gut. (2002) 50 (Suppl
3): iii54-9.
110. Chakraborti CK. New-found link between
microbiota and obesity. World. J. Gastrointest.
Pathophysiol. (2015) 6: 110-9.
111. Barrett HL, Dekker Nitert M, Conwell LS and
Callaway LK. Probiotics for preventing gestational
diabetes. Cochrane Database Syst. Rev. (2014):
Cd009951.
112. Hersoug LG, Moller P and Loft S. Gut microbiotaderived lipopolysaccharide uptake and trafficking
to adipose tissue: implications for inflammation
and obesity. Obesity Reviews (2016) 17: 297-312.
113. Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, da
Silva NF, Sabico SL and Kumar S. Changes in
endotoxin levels in T2DM subjects on anti-diabetic
therapies. Cardiovasc. Diabetol. (2009) 8: 20.
114. Turnbaugh PJ, Backhed F, Fulton L and Gordon
JI. Diet-induced obesity is linked to marked but
reversible alterations in the mouse distal gut
microbiome. Cell. Host. Microbe. (2008) 3: 213-23.
115. Alard J, Lehrter V, Rhimi M, Mangin I, Peucelle
V and Abraham AL. Beneficial metabolic effects
of selected probiotics on diet-induced obesity
and insulin resistance in mice are associated with
improvement of dysbiotic gut microbiota. Environ.
Microbiol. (2016) 18: 1484-97.
116. Amar J, Chabo C, Waget A, Klopp P, Vachoux C
and Bermudez-Humaran LG. Intestinal mucosal
adherence and translocation of commensal bacteria
at the early onset of type 2 diabetes: molecular
mechanisms and probiotic treatment. EMBO. Mol.
Med. (2011) 3: 559-72.
117. Saez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda
FJ, Plaza-Diaz J and Gil A. Effects of Probiotics
and Synbiotics on Obesity, Insulin Resistance
Syndrome, Type 2 Diabetes and Non-Alcoholic
Fatty Liver Disease: A Review of Human Clinical
Trials. Int. J. Mol. Sci. (2016)17: pii: E928.
118. Honda K, Moto M, Uchida N, He F and Hashizume
N. Anti-diabetic effects of lactic acid bacteria in
normal and type 2 diabetic mice. J. Clin. Biochem.
Nutr. (2012) 51: 96-101.
119. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A,
Niafar M, Asghari-Jafarabadi M and Mofid V.
Probiotic yogurt improves antioxidant status in
type 2 diabetic patients. Nutrition (2012) 28: 539-
43.
120. Miljković D and Spasojević I. Multiple
sclerosis: molecular mechanisms and therapeutic
opportunities. Antioxid. Redox. Signal. (2013) 19:
2286-334.
121. Verkhratsky A and Butt A. Glial neurobiology: a
textbook: John Wiley & Sons (2007).
122. Bubnov RV, Spivak MY, Lazarenko LM, Bomba
A and Boyko NV. Probiotics and immunity:
provisional role for personalized diets and disease
prevention. EPMA (2015) 6: 14.
123. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart
JM, Conti P and Theoharides TC. Gut-microbiotabrain axis and its effect on neuropsychiatric
disorders with suspected immune dysregulation. 
50
Taherian M et al. / IJPR (2019), 18 (Special Issue): 31-50
Clin. Ther. (2015) 37: 984-95.
124. Goudarzvand M, Javan M, Mirnajafi-Zadeh
J, Mozafari S and Tiraihi T. Vitamins E and
D3 attenuate demyelination and potentiate
remyelination processes of hippocampal formation
of rats following local injection of ethidium
bromide. Cell Mol. Neurobiol. (2010) 30: 289-99.
125. Van Rensburg S, Kotze M, Hon D, Haug P, Kuyler
J and Hendricks M. Iron and the folate-vitamin
B12-methylation pathway in multiple sclerosis.
Metab. Brain Dis. (2006) 21: 117-33.
126. van Toorn R, Schoeman JF, Solomons R, Rensburg
MA and van Rensburg SJ. Iron status in children
with recurrent episodes of tumefactive cerebral
demyelination. J. Child. Neurol. (2010) 25: 1401-7.
127. Keirstead HS. Stem cells for the treatment of
myelin loss. Trends. Neurosci. (2005) 28: 677-83.
128. Hill T, Brennan L, O’Connor A, Scully L, Healy S
and O’Sullivan A. Effect of probiotic and vitamin
D supplementation on markers of vitamin D status
and bone turnover in healthy adults. Proc. Nutr.
Soc. (2009) 68 (OCE3).
129. Lavasani S, Dzhambazov B, Nouri M, Fåk F, Buske
S and Molin G. A novel probiotic mixture exerts
a therapeutic effect on experimental autoimmune
encephalomyelitis mediated by IL-10 producing
regulatory T cells. PloS One (2010) 5: e9009.
130. Li Q and Zhou J-M. The microbiota–gut–brain axis
and its potential therapeutic role in autism spectrum
disorder. Neuroscience (2016) 324: 131-9.
131. Braniste V, Al-Asmakh M, Kowal C, Anuar F,
Abbaspour A and Tóth M. The gut microbiota
influences blood-brain barrier permeability in mice.
Sci. Transl. Med. (2014) 6 :263ra158-263ra158.
132. Marteau P, Pochart P, Bouhnik Y and Rambaud JC.
Fate and effects of some transiting microorganisms
in the human gastrointestinal tract. W. Rev. Nut.
Diet. (1993) 74: 1-21.
133. Kim S, Covington A and Pamer EG. The intestinal
microbiota: antibiotics, colonization resistance,
and enteric pathogens. Immunol. Rev. (2017) 279:
90-105.
134. Marteau P and Shanahan F. Basic aspects and
pharmacology of probiotics: an overview of
pharmacokinetics, mechanisms of action and
side-effects. Best practice & research. Clin.
Gastroenterol. (2003) 17: 725-40.
135. Dorota Zielin´ska, Barbara Sionek and Danuta
Kołoz˙yn-Krajewska. Chapter 6 Safety of
Probiotics. Diet Microbiome Health (2018) 8-25.
136. Quin C, Estaki M, Vollman D M, Barnett J A, Gill
S K and Gibson DL. Probiotic supplementation
and associated infant gut microbiome and health:
a cautionary retrospective clinical comparison. Sci.
Rep. (2018) 8: 82-3.
137. Castro González JM, Castro P, Sandoval H
and Castro-Sandoval D. Probiotic lactobacilli
precautions. Front Microbiol. (2019) 10: 375